2 not yet recruiting. 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Huijie Zhang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D Ivarmacitinib, Placebo - T1DM - Type 1 Diabetes Mellitus | Phase 2 | Not yet recruiting | Huijie Zhang | 132 | 2026-09-30 | 2026-09-29 |
| QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy empagliflozin, Finerenone, Mazdutide - Type 2 Diabetic Kidney Disease | Phase 4 | Not yet recruiting | Huijie Zhang | 820 | 2026-09-01 | 2026-08-20 |
Angiotensin Receptor Antagonists (1) · empagliflozin (1) · finerenone (1) · ivarmacitinib (1) · mazdutide (1)
China (2)